+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in Belgium



Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in Belgium



Acta Psychiatrica Scandinavica. Supplementum 360: 52-53



Moclobemide was compared with amitriptyline for antidepressant efficacy, safety and tolerance. Two studies were conducted, both over at least 4 weeks; in the first, 8 patients were given moclobemide in doses ranging from 300 to 328 mg, and 9 patients amitriptyline in doses of 75 to 96 mg; in the second, the numbers were 13 on moclobemide and 14 on amitriptyline, and the mean doses were 294-408 mg and 95-129 mg respectively. Both studies showed the 2 treatments to be equally effective, and there were no significant differences at any point. Moclobemide appeared slightly more effective and slightly better tolerated than amitriptyline, but the numbers were too small for any valid conclusion.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040711161

Download citation: RISBibTeXText

PMID: 2248072


Related references

Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium. Acta Psychiatrica Scandinavica. Supplementum 360: 50-51, 1990

An Australian multicentre study of moclobemide versus amitriptyline in the treatment of depression. Australian and New Zealand Journal of Psychiatry 26(3): 454-458, 1992

Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium. Acta Psychiatrica Scandinavica. Supplementum 360: 42-42, 1990

A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression. Journal of Clinical Psychopharmacology 15(4 Suppl 2): 41s-45s, 1995

A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 37 Suppl 1: 12-17, 1992

A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders. Australian and New Zealand Journal of Psychiatry 24(4): 475-479, 1990

Moclobemide ro 11 1163 vs. clomipramine in the treatment of depression a double blind multicenter study in belgium. Drug Development Research 21(4): 325-332, 1990

A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Australian and New Zealand Journal of Psychiatry 27(1): 49-55, 1993

Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. International Clinical Psychopharmacology 14(6): 321-327, 1999

Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatrica Scandinavica 104(2): 104-109, 2001

Fluoxetine and moclobemide versus amitriptyline in major depression: A single blind randomized clinical trial in Zimbabwe. Central African Journal of Medicine 43(2): 38-40, 1997

Moclobemide versus fluoxetine for double depression: A randomized double-blind study. Journal of Psychiatric Research 30(6): 453-458, 1996

Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. International Clinical Psychopharmacology 13(2): 63-73, 1998

A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. Journal of Psychopharmacology 10(3): 235-240, 1996